Evidence map›Paper›PMID 35214766›Full record

ArticleVaccines2022

Protease-Based Subunit Vaccine in Mice Boosts BCG Protection against

Ana Paula Junqueira-Kipnis, Carine de Castro Souza, Ana Carolina de Oliveira Carvalho, Fabio Muniz de Oliveira, Vinnycius Pereira Almeida, Alisson Rodrigues de Paula, Mara Rubia Celes, André Kipnis

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ana Paula Junqueira-KipnisDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.ORCID 0000-0002-4200-6617
Carine de Castro SouzaDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.
Ana Carolina de Oliveira CarvalhoDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.
Fabio Muniz de OliveiraDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.ORCID 0000-0002-4470-8444
Vinnycius Pereira AlmeidaDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.ORCID 0000-0002-3635-7787
Alisson Rodrigues de PaulaDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.
Mara Rubia CelesDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.ORCID 0000-0002-4733-007X
André KipnisDepartment of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil.ORCID 0000-0001-5950-106X
Universidade Federal de Goiás · BR

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001National Council for Scientific and Technological Development 303671/2019-0National Council for Scientific and Technological Development 314366/2020-2National Council for Scientific and Technological Development 406868/2016-6National Council for Scientific and Technological Development 421867/2018-3
6 · The paper itself

Abstract

The significant number of people with latent and active tuberculosis infection requires further efforts to develop new vaccines or improve the Bacillus Calmette-Guérin (BCG), which is the only approved vaccine against this disease. In this study, we developed a recombinant fusion protein (PEPf) containing high-density immunodominant epitope sequences from Rv0125, Rv2467, and Rv2672

Indexed as

adjuvantAdvax4Msh1PepA/Mtb32aPepNrecombinant BCGsubunit vaccinetuberculosis

Identifiers

PMID35214766
PMCPMC8877678
OpenAlexW4212766456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.